Current Report Filing (8-k)

Date : 09/30/2019 @ 8:40PM
Source : Edgar (US Regulatory)
Stock : Inspyr Therapeutics, Inc. (QB) (NSPX)
Quote : 0.0084  -0.0006 (-6.67%) @ 9:00PM

Current Report Filing (8-k)












Pursuant to Section 13 or 15(d)

of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): September 30, 2019




Inspyr Therapeutics, Inc.

(Exact name of registrant as specified in Charter)


Delaware   000-55331   20-0438951
(State or other jurisdiction of
incorporation or organization)
  (Commission File No.)   (IRS Employee
Identification No.)


31200 Via Colinas, Suite 200

Westlake Village CA 91362

(Address of Principal Executive Offices)



(Issuer Telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 5.03 Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.


As previously disclosed in the Definitive Proxy Statement filed by Inspyr Therapeutics, Inc. (the “Company”) on January 22, 2019, on January 7, 2019, pursuant to a written consent, the Company’s shareholders approved a proposal authorizing the board of directors of the Company (“Board”) to effect a reverse stock split of the Company’s common stock, par value $0.0001 (the “Common Stock”).


On September 17, 2019, the Board approved a one-for-twenty five (1-for-25) reverse stock split of the Common Stock (“Reverse Stock Split”). In furtherance of the Reverse Stock Split, the Company has filed an amended and restated certificate of incorporation (“Certificate of Incorporation”) with the Secretary of State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. Eastern Time on September 30, 2019 (“Effective Time”). Accordingly, at the Effective Time, each of the Company’s Common Stock shareholders will receive one (1) new share of Common Stock for every twenty five (25) shares such shareholder held immediately prior to the Effective Time. The Reverse Stock Split will also affect the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and will result in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. No fractional shares will be issued as a result of the Reverse Stock Split. Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number of shares.


As a result of the Reverse Stock Split, the number of issued and outstanding shares of Common Stock will be adjusted from 150,000,000 shares to approximately 6,000,000 shares. The number of authorized shares of Common Stock and preferred stock under the Certificate of Incorporation remains the same.


Pursuant to the terms of their Certificates of Designation, each Series of the Company’s preferred stock will have the conversion price at which shares of such applicable preferred stock may be converted into shares of Common Stock proportionately adjusted to reflect the Reverse Stock Split.


The Common Stock will begin trading on post Reverse Stock Split basis on Pink Sheets of the OTC Markets Group when the market opens on October 1, 2019. The Company’s trading symbol will remain “NSPX.”. The new CUSIP number for the Common Stock following the Reverse Stock Split is 45782A 304.


The information set forth herein is qualified in its entirety by the terms contained in the Certificate of Incorporation, a copy of which is attached to this report as Exhibit 3.01(i).


Item 9.01 Financial Statement and Exhibits.


Exhibit No.   Description
3.01(i)   Amended and Restated Certificate of Incorporation 








Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: September 30, 2019


  Inspyr Therapeutics, Inc.
By: /s/ Michael Cain
    Michael Cain
Chief Executive Officer







Exhibit No.   Description
3.01(i)   Amended and Restated Certificate of Incorporation 




Inspyr Therapeutics, Inc. (USOTC:NSPX)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Inspyr Therapeutics, Inc. Charts.

Inspyr Therapeutics, Inc. (USOTC:NSPX)
Intraday Stock Chart

Today : Wednesday 11 December 2019

Click Here for more Inspyr Therapeutics, Inc. Charts.

Latest NSPX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.